The Respiratory Care Market – Factors Driving the Market and Opportunities for Inspira Technologies’ Products
In the last few years, especially during the COVID-19 pandemic, numerous reports and publications have predicted an increase in demand for critical care equipment, such as invasive mechanical ventilation machines and extracorporeal life support systems.
The increasing prevalence of chronic disorders and an increasing geriatric population, which is typically at a high risk of these diseases, are factors expected to drive the market for invasive mechanical ventilation machines and extracorporeal life support systems. The COVID-19 pandemic has further boosted the demand for respiratory care systems and technologies. Experts estimate that the pandemic will have a long-term effect on patients, some of whom may even deteriorate to acute respiratory failure.
According to the estimates published by the World Health Organization (WHO), the global population aged 60 years and above is expected to increase to 2 billion by 2050. The respiratory care market is anticipated to be primarily driven by a large geriatric population suffering from respiratory diseases which can be attributed to poor immunity, resulting in greater susceptibility of requiring invasive mechanical ventilation machines and extracorporeal life support systems.
In addition, according to forecasts in the invasive mechanical ventilation market, Inspira Technologies Oxy B.H.N. Ltd.’s (the “Company”) patient population target market for the ART system, an early-stage extracorporeal respiratory support system, is expected to grow steadily in the coming years. The global invasive mechanical ventilation market size was valued at $7.24 billion in 2020 and is expected to record a compound annual growth rate (CAGR) of 4.9% from 2022 to 2028.
The global extracorporeal membrane oxygenation (ECMO) market, Inspira Technologies’ extracorporeal life support (ECLS) target market, is projected to reach $673.8 million by 2026 from $531.1 million in 2021, at a CAGR of 4.9%. The growth of the global ECMO market is mainly driven by factors such as the increasing prevalence of cardiovascular and respiratory diseases, the growing adoption of ECMO in lung transplantation procedures, growth in the number of ECMO centers, and technological advancements in ECMO machines.
Inspira Technologies is a breakthrough company in the medical device arena which is developing two advanced systems in its pipeline. The first is the ECLS system that will be available in the near future; the second is its novel technology, the ART system – a low flow hemo protective early-stage extracorporeal system, designed to rebalance patients’ saturation levels while they are awake and spontaneously breathing.
During the COVID-19 pandemic, the medical community has gained experience with extracorporeal life support systems, and the Company expects that this experience will assist with its market penetration and product deployment.
For more information, please search our knowledge center and the updated investors’ deck.
About Inspira Technologies OXY B.H.N. Ltd.
Inspira Technologies is an innovative medical device company in the respiratory care industry. Inspira is developing the ART system, a cost effective early extracorporeal respiratory support system with an intent to function as an “Artificial Lung” for deteriorating respiratory patients. The ART is designed to utilize a hemo-protective flow approach aimed at rebalancing oxygen saturation levels while patients are awake and breathing, potentially minimizing the patient’s need for mechanical ventilation. The Company’s product has not yet been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA) or the CE or other required regulatory agencies.
For more information, please visit our corporate website: www.inspirao2.com
Forward Looking Statement
This newsletter contains express or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, the Company is using forward-looking statements when it discusses the potential market and need for invasive mechanical ventilation machines and extracorporeal life support systems, the potential benefits of Inspira Technologies’ products and the potential for the market penetration and product development of its products. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s Registration Statement on Form F-1 filed with the SEC, as well as its subsequent public filings, which are available on the SEC’s website, www.sec.gov.
 Grand View Research Invasive Mechanical Ventilation Market Analysis and Segment Forecast to 2028 | Extracorporeal membrane oxygenation machine market forecasts to 2026, MarketsandMarkets
 Grand View Research Invasive Mechanical Ventilation Market Analysis and Segment Forecast to 2028
 Extracorporeal membrane oxygenation machine market forecasts to 2026, MarketsandMarkets